Intelligenza artificiale autonoma e diagnosi ottica umana assistita dall’intelligenza artificiale (CADx-Prosp)
Intelligenza artificiale autonoma e diagnosi ottica umana assistita dall'intelligenza artificiale dei polipi colorettali: uno studio randomizzato e controllato
Computer-aided image-enhanced endoscopy can predict the nature of colorectal polyps with over 90% accuracy. This technology uses artificial intelligence (AI) to analyze video recordings of polyps, learning to make diagnoses in real-time. This means that doctors can get immediate predictions about small polyps during the procedure, reducing the need for separate pathology exams and saving costs, ultimately improving patient care.
Human and AI interactions are complex and a framework to reap synergistic effects CADx systems when used by humans to harness optimal performance needs to be established. AI solutions in medicine are usually developed to be used as assistive devices, however, then they rely on humans to correct AI errors. Optical polyp diagnosis is a complex task. Non experts usually achieve diagnostic accuracy in 70-80%. CADx systems have a similar diagnostic accuracy when used autonomously. Clinical evaluation of CADx systems showed that CADx assisted OD performs equally to the operator performance when using non CADx assisted OD. To harness a benefit of clinical CADx implementation we would have to find a way that synergies between human and CADx come into play to eliminate cases in which CADx assisted and/ or human OD results in low diagnostic accuracy and also addresses the problem of serrated polyp recognition.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Our study hypothesis is that for CADx implementation, instead of using the high/low confidence framework, identifying cases with suboptimal diagnostic accuracy could be facilitated through identifying cases in which CADx and endoscopist disagreed in their diagnosis. Eliminating such cases might separate out cases with low accuracy when using CADx assisted OD. Since endoscopists have a high sensitivity but low specificity for serrated polyp OD, this framework will also allow us to implement a strategy to adequately manage serrated polyps found in the cohort.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Daniel von Renteln, MD
- Numero di telefono: 30912 514 890-8000
- Email: daniel.von.renteln.med@ssss.gouv.qc.ca
Luoghi di studio
-
-
Quebec
-
Montreal, Quebec, Canada
- Reclutamento
- Ghislaine Ahoua
-
Contatto:
- Daniel von Renteln, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Indication for full colonoscopy.
Exclusion Criteria:
- Known inflammatory bowel disease
- Active colitis
- coagulopathy
- familial polyposis syndrome
- poor general health, defined as an American Society of Anesthesiologists class >3
- emergency colonoscopy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: All participants
The endoscopist will make an optical diagnosis (OD) prediction for all small polyps (up to 10 mm) in white light (WL). Then, the endoscopist will make another OD prediction using image enhanced endoscopy (IEE) modes. After that, CADx will be activated in the IEE mode and a CADx prediction will be documented. Finally, after seeing the CADx prediction, the endoscopist will make a final prediction, which can agree or disagree with the autonomous CADx one. Polyps will be resected and sent to a pathology lab, where a pathologic diagnosis (blinded to the endoscopist's predictions) will be rendered. |
The CADx system will be used to predict the histopathology of the polyp detected. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis
Lasso di tempo: up to 100 weeks
|
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis , when histopathology results are used as the reference |
up to 100 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis
Lasso di tempo: up to 100 weeks
|
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis, when histopathology results are used as the reference |
up to 100 weeks
|
|
Test characteristics, including recall, specificity, positive and negative predictive values (PPV/NPV), and particularly the NPV of rectosigmoid neoplastic polyps.
Lasso di tempo: up to 100 weeks
|
A ≥90% NPV will be used as a quality benchmark for a strategy to not resect such diminutive polyps. |
up to 100 weeks
|
|
Agreement of surveillance interval recommendations of AI-A and AI-H compared with the pathology-based recommendations
Lasso di tempo: up to 100 weeks
|
For surveillance interval assignment, the pathology results of concomitant polyps >5 mm (including multiple concomitant polyps of all sizes and histology) will be considered when calculating the surveillance interval recommendation. Surveillance recommendations will be based on the 2020 United States Multi Society Task Force Guidelines as is current standard of practice at our center. |
up to 100 weeks
|
|
Proportion of patients for whom an immediate surveillance recommendation can be directly provided for each approach, and how often histopathology-based polyp examination would have been avoided.
Lasso di tempo: up to 100 weeks
|
The potential cost-effectiveness of OD (either approaches) will be evaluated using the measured described above. |
up to 100 weeks
|
|
Variability of OD (AI-A and AI-H) across participating endoscopists.
Lasso di tempo: up to 100 weeks
|
Each participating endoscopist will conduct a similar number of optical diagnoses to assess endoscopist-related factors. |
up to 100 weeks
|
|
Cost-effectiveness of OD ((AI-A and AI-H)
Lasso di tempo: up to 100 weeks
|
A cost-effectiveness model will be applied to better quantify costs and understand cost impact including key cost drivers when generalized to a broader screening population. |
up to 100 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Daniel von Renteln, MD, University of Montreal Medical Center (CHUM)
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2025-12306
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .